Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06607523 · ClinicalTrials.gov registry record · NA

The Gut-Brain Axis During Neurorehabilitation; Prebiotic Treatment to Alter the Gut Microbiome and Neurologic Symptoms

A NA study of Brain Injuries, sponsored by The University of Texas Medical Branch, Galveston.

Recruiting
Registry status
NA
Development phase
130
Enrollment target
1
Study location

NCT06607523 is a NA study of Brain Injuries that is actively recruiting participants, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 130 participants, below the 325-participant average among 22 other Brain Injuries trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06607523, a NA study of Brain Injuries, is actively recruiting participants, sponsored by The University of Texas Medical Branch, Galveston.

RECRUITING
Registry status
NA
Development phase
130 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to characterize the microbiome of patients undergoing post-acute residential neurorehabilitation compared to community controls and to determine if a dietary fiber, Inulin, can create a shift in the microbiome leading to changes in fatigue and cognition.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Inulin

Study Locations (1)

Texas

  • University of Texas Medical Branch - Galveston

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2025-03-06
Est. Completion 2028-10-01
Phase NA

What the Registry Record Tells You About NCT06607523

The ClinicalTrials.gov registry entry for NCT06607523 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 325-participant average among 22 other Brain Injuries trials with a reported enrollment target (60% lower). The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain Injuries appearing as the primary indexed condition, and to 1 intervention - of which Inulin is the first listed.

NCT06607523 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06607523 about?

NCT06607523 is a clinical study titled "The Gut-Brain Axis During Neurorehabilitation; Prebiotic Treatment to Alter the Gut Microbiome and Neurologic Symptoms". The aim of this study is to characterize the microbiome of patients undergoing post-acute residential neurorehabilitation compared to community controls and to determine if a dietary fiber, Inulin, can create a shift in the microbiome leading to changes in fatigue and cognition.

What is the current status of trial NCT06607523?

This trial is currently recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2025-03-06. Estimated completion is 2028-10-01.

What conditions does trial NCT06607523 study?

This clinical trial studies the following conditions: Brain Injuries.

What interventions are being tested in trial NCT06607523?

The interventions under investigation include: Inulin (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06607523?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06607523 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Brain Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.